Atom Investors LP Lowers Holdings in Danaher Corporation $DHR

Atom Investors LP decreased its position in Danaher Corporation (NYSE:DHR) by 18.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 19,861 shares of the conglomerate’s stock after selling 4,515 shares during the period. Atom Investors LP’s holdings in Danaher were worth $4,547,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of DHR. JPL Wealth Management LLC purchased a new stake in Danaher during the third quarter worth $25,000. Elevated Capital Advisors LLC purchased a new stake in Danaher during the fourth quarter worth $26,000. WFA of San Diego LLC purchased a new stake in Danaher during the second quarter worth $26,000. ANTIPODES PARTNERS Ltd purchased a new stake in Danaher during the third quarter worth $27,000. Finally, Hilton Head Capital Partners LLC purchased a new stake in Danaher during the fourth quarter worth $27,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

NYSE DHR opened at $181.57 on Wednesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.87 and a quick ratio of 1.52. The stock’s fifty day moving average price is $180.54 and its 200 day moving average price is $203.94. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80. The company has a market cap of $128.51 billion, a price-to-earnings ratio of 35.12, a PEG ratio of 2.31 and a beta of 0.81.

Danaher (NYSE:DHR) last released its earnings results on Monday, April 20th. The conglomerate reported $2.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.94 by $0.12. Danaher had a return on equity of 10.91% and a net margin of 14.89%.The firm had revenue of $5.95 billion for the quarter, compared to the consensus estimate of $6 billion. During the same period in the prior year, the firm earned $1.88 EPS. The firm’s revenue was up 3.7% on a year-over-year basis. As a group, equities research analysts forecast that Danaher Corporation will post 8.45 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Friday, June 26th will be given a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Friday, June 26th. Danaher’s dividend payout ratio is presently 30.95%.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. UBS Group lowered their target price on Danaher from $270.00 to $250.00 and set a “buy” rating for the company in a report on Wednesday, April 22nd. Evercore upped their target price on Danaher from $225.00 to $232.00 and gave the stock an “outperform” rating in a report on Tuesday, April 21st. Robert W. Baird lowered their target price on Danaher from $251.00 to $249.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Piper Sandler assumed coverage on Danaher in a research report on Thursday, June 11th. They set a “neutral” rating and a $200.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Danaher in a research report on Friday, March 27th. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $233.61.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.